Johnson & Johnson Slides 5.3% to $250.09 Following Morning Earnings

Johnson & Johnson reported earnings before the opening bell, missing expectations relative to the $2.53 EPS estimate. The stock immediately came under pressure across the cash session, tumbling 5.3% to trade at $250.09. That marks a direct $13.93 decline from its prior close at $264.02, slicing into roughly $33 billion of equity value for the $630.0 billion healthcare heavyweight. The sharp reaction follows a broader run of corporate earnings prints crossing the tape, where execution misses are being treated aggressively by the floor. With JNJ shedding over five percent in a single morning, defensive names are finding little haven status when bottom-line numbers do not clear the bar. Yet despite the heavy single-stock drag on large-cap benchmarks, the broader index dealer book is not showing structural breakdown. SPY sits at 777.29, maintaining its position above its gamma flip at 774.63 in positive gamma territory. With the SPY put wall planted right at 777 and the call wall overhead at 779, dealers remain positioned as natural shock absorbers on the headline tape, dampening downside continuation rather than magnifying it. Over in tech, QQQ tells a slightly different story, trading at 743.81 below its 745.37 flip, remaining trapped in short gamma where intraday dealer hedging leans pro-cyclical between its 740 put wall and 748 call wall. Small caps on IWM mirror SPY's stability, holding at 276.4 above a 274.33 flip and pinning its 276 put wall. The market is absorbing JNJ's outsized corporate drawdown within defined index ranges, even as single-stock volatility punishes unhedged earnings holds.